Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
29/09/26	¥31.00	-3.12%	989,500
28/09/26	¥32.00	-3.03%	192,100
25/09/26	¥33.00	0.00%	253,500

Delayed Quote Japan Exchange

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange 09:30:00 29/09/2026 +03			5-day change	1st Jan Change
31.00 ^JPY	-3.12%		-6.06%	-44.64%

09-11	Exegenesis Bio and Modalis Therapeutics Corporation Collaborate To Advance MDL-201 For Duchenne Muscular Dystrophy	CI
08-10	Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	3.3B 20.93M 18.47M 17.48M 15.85M 29.71M 2.01B 30.01M 210M 80.8M 1.03B 78.59M 76.88M	P/E 2024	-3.57x	P/E 2025	-2.01x
Enterprise Value	488M 3.1M 2.73M 2.59M 2.35M 4.4M 297M 4.44M 31.02M 11.96M 152M 11.63M 11.38M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	91.39%	Yield 2024 *	-	Yield 2025	-

09-11	Exegenesis Bio and Modalis Therapeutics Corporation Collaborate To Advance MDL-201 For Duchenne Muscular Dystrophy	CI
08-10	Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-12	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-27	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-13	Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-12	Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25/08/25	Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC	CI
07/08/25	Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC	CI
07/07/25	Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment	MT
16/06/25	Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan	MT
09/06/25	SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy	CI
01/05/25	Modalis Issues 21,900 Shares for Restricted Stock Remuneration	MT
27/01/25	Modalis Therapeutics Secures Japanese Patent for Gene Therapy	MT

09-11	Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy	BU
12-25	Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD	BU
13/05/25	Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.	BU
06/01/25	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	BU
28/10/24	Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration	AQ

Modalis Therapeutics Corporation Stock

Stocks

4883

JP3922600006

Biotechnology & Medical Research

Valuation: Modalis Therapeutics Corporation

Chart: Modalis Therapeutics Corporation

Latest news: Modalis Therapeutics Corporation

Press Releases: Modalis Therapeutics Corporation

Quotes and Performance

Price Extremes

Managers and Directors: Modalis Therapeutics Corporation

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 day	-3.13%
1 week	-6.06%
Current month	-8.82%
1 month	-6.06%
3 months	+3.33%
6 months	-46.55%
Current year	-44.64%

Manager	Title	Age	Since
Haru Morita CEO	Chief Executive Officer	57	01/01/2016
Naoki Kobayashi DFI	Director of Finance/CFO	63	-
Tetsuya Yamagata CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Haru Morita BRD	Director/Board Member	57	01/01/2016
Osamu Nureki BRD	Director/Board Member	60	01/01/2016
Hideki Takeda BRD	Director/Board Member	68	01/01/2016

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/24/24 A	Osamu Nureki	Others	Founder	10,000	0.0220%
9/24/24 A	Osamu Nureki	Others	Founder	10,000	0.0220%
9/24/24 A	Osamu Nureki	Others	Founder	6,000	0.0132%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MODALIS THERAPEUTICS CORPORATION	-3.12%	-6.06%	-62.20%	-79.74%	21.64M
WUXI APPTEC CO., LTD.	-0.70%	-4.35%	+56.10%	+86.42%	71.81B
ARGENX SE	+0.45%	-0.82%	+38.81%	+84.19%	60.06B
WUXI BIOLOGICS (CAYMAN) INC.	+0.19%	+0.94%	+36.97%	+21.32%	27.93B
INSMED INCORPORATED	-1.63%	-4.28%	-18.36%	+358.00%	25.7B
BIONTECH SE	-0.45%	-2.18%	+0.59%	-9.17%	24.89B
GENMAB A/S	+0.65%	+1.67%	+26.47%	-7.62%	20.92B
PHARMAESSENTIA CORPORATION	+3.46%	+3.91%	+158.90%	+337.81%	15.04B
EXELIXIS, INC.	+0.98%	+1.05%	+44.84%	+168.92%	14.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.91%	-4.56%	-2.71%	+506.41%	13.87B
Average	+0.37%	-1.13%	+27.94%	+146.66%	27.47B
Weighted average by Cap.	+0.23%	-1.74%	+38.18%	+128.20%

	2024	2025
Net sales	-	-
Net income	-1.32B -8.35M -7.37M -6.97M -6.32M -11.86M -801M -11.97M -83.66M -32.24M -409M -31.36M -30.68M	-2.15B -13.65M -12.04M -11.4M -10.33M -19.38M -1.31B -19.57M -137M -52.69M -669M -51.25M -50.13M
Net Debt	-3.58B -22.67M -20.01M -18.93M -17.17M -32.19M -2.18B -32.5M -227M -87.53M -1.11B -85.13M -83.28M	-2.81B -17.83M -15.74M -14.89M -13.5M -25.32M -1.71B -25.57M -179M -68.85M -874M -66.96M -65.51M

1 week	31	34
1 month	31	50
Current year	29	83
1 year	29	83
3 years	29	203
5 years	29	1,397
10 years	29	4,070